Serono (virt-x: SEO and NYSE: SRA) and Syntonix Pharmaceuticals Inc. have entered into an agreement under which the companies will evaluate Syntonix' FSH:Fc SynFusion™ products for further development.
The SynFusion™ and Transceptor™ technologies of Syntonix could lead to the development of a long-acting FSH (follicle-stimulating hormone) therapy for the treatment of infertility that can be inhaled and less frequently-dosed, instead of daily injection.
Serono, a world leader in the treatment of infertility, currently markets GONAL-f® (follitropin alfa), a highly consistent recombinant human follicle-stimulating hormone (r-hFSH) that has been approved in over 90 countries worldwide including Europe and the United States and is now the most widely prescribed gonadotropin in the world.
The terms of agreement between Serono and Syntonix include the following:
Other financial terms were not disclosed.
Find more details from the full press release at Serono, Syntonix (a pdf file) or PR Newswire.
Comment Preview